These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 4462871)

  • 21. Mortality among Parkinson patients treated with L-dopa combined with a decarboxylase inhibitor.
    Zumstein H; Siegfried J
    Eur Neurol; 1976; 14(5):321-8. PubMed ID: 949985
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Decarboxylase inhibitor given in combination with l-dopa. A new therapeutic principal in parkinsonism].
    Dietrichson P
    Tidsskr Nor Laegeforen; 1973 Oct; 93(28):2113-5. PubMed ID: 4590070
    [No Abstract]   [Full Text] [Related]  

  • 23. [Development of studies on the treatment of Parkinson syndromes using levodopa. I. Short- and medium-term (2 years) effects of the combination levodopa decarboxylase inhibitor].
    Rondot P; Ribadeau Dumas JL; Cardon P
    Therapie; 1975; 30(5):653-66. PubMed ID: 769245
    [No Abstract]   [Full Text] [Related]  

  • 24. Levodopa with benserazide or carbidopa in Parkinson disease.
    Rinne UK; Mölsä P
    Neurology; 1979 Dec; 29(12):1584-9. PubMed ID: 574221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Madopar HBS and the decompensated phase of Parkinson disease.
    Caraceni T; Nordera N; Lamperti E; Lorizio A
    Ital J Neurol Sci; 1989 Aug; 10(4):407-14. PubMed ID: 2793413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Disappearance of the disordered postural regulation of cerebral circulation by the addition of benserazide in parkinsonism treated with L-dopa].
    Boismare F; Samson M; Pouliquen A; Hacpille L
    Therapie; 1976; 31(5):615-22. PubMed ID: 1013953
    [No Abstract]   [Full Text] [Related]  

  • 27. [Our experience in the treatment of Parkinson's disease with L-dopa plus RO 4-4602 combination].
    Campanella G; Pennetta R
    Acta Neurol (Napoli); 1974; 29(3):252-63. PubMed ID: 4417098
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparison of levodopa with carbidopa or benserazide in parkinsonism.
    Greenacre JK; Coxon A; Petrie A; Reid JL
    Lancet; 1976 Aug; 2(7982):381-4. PubMed ID: 73849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Madopar HBS in fluctuating parkinsonian patients: two-year treatment.
    Pezzoli G; Tesei S; Ferrante C; Cossutta E; Zecchinelli A; Scarlato G
    Mov Disord; 1988; 3(1):37-45. PubMed ID: 3050471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Combined (surgical and drug) therapy of parkinsonism].
    Kandel' EI; Iadgarov IS
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1984; 84(8):1157-61. PubMed ID: 6388198
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Analysis of a therapeutic failure of L-Dopa: can Adams-Van Bosaert and Van Der Eecken's strio-nigral degeneration be diagnosed during the patient's life?].
    André JM; Royer RJ; Duc M; Kissel P
    Rev Neurol (Paris); 1974; 130(7-8):322-6. PubMed ID: 4453761
    [No Abstract]   [Full Text] [Related]  

  • 32. Six-year results of treatment with levodopa plus benzerazide in Parkinson's disease.
    Barbeau A; Roy M
    Neurology; 1976 May; 26(5):399-404. PubMed ID: 944392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Levodopa treatment of Parkinson's syndrome: past and future.
    Pletscher A
    Adv Neurol; 1990; 53():469-73. PubMed ID: 2239486
    [No Abstract]   [Full Text] [Related]  

  • 34. [Results of prolonged treatment of Parkinson's disease with the L-dopa-benserazide combination].
    Casacchia M; Barba C; Ruggieri S; Zamponi A; Agnoli A
    Riv Neurol; 1974; 44(5):303-30. PubMed ID: 4217465
    [No Abstract]   [Full Text] [Related]  

  • 35. Study of deterioration in long-term treatment of parkinsonism with L-dopa plus decarboxylase inhibitor.
    Ludin HP; Bass-Verrey F
    J Neural Transm; 1976; 38(3-4):249-58. PubMed ID: 956811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dopa-unresponsive pure akinesia or freezing. A condition within a wide spectrum of PSP?
    Imai H; Nakamura T; Kondo T; Narabayashi H
    Adv Neurol; 1993; 60():622-5. PubMed ID: 8420201
    [No Abstract]   [Full Text] [Related]  

  • 37. Letter: Levodopa and dopadecarboxylase in treatment of postural hypotension.
    Boismare F; Boquet J
    Br Med J; 1975 Mar; 1(5957):573. PubMed ID: 1139159
    [No Abstract]   [Full Text] [Related]  

  • 38. [L-dopa therapy of parkinson syndrome].
    Kapfhammer HP; Kuss HJ; Rüther E
    Nervenarzt; 1985 Feb; 56(2):57-68. PubMed ID: 3920542
    [No Abstract]   [Full Text] [Related]  

  • 39. [The association of L-DOPA and Ro 4-4602 in the treatment of Parkinson's disease (author's transl)].
    Campanella G; Pennetta R
    Riv Patol Nerv Ment; 1974 Oct; 95(5):673-5. PubMed ID: 4470267
    [No Abstract]   [Full Text] [Related]  

  • 40. Response to Sinemet 25/100 in Parkinson's disease.
    Ulm G; Gerdes U; Lehmann K
    Adv Neurol; 1984; 40():541-7. PubMed ID: 6695634
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.